Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

FreshSplash/Getty Images Researchers report that GLP-1 drugs prescribed for weight loss, like Ozempic and Mounjaro, may improve cognition and lower dementia and cardiovascular disease risk.

Similarly, Zepbound is Mounjaro's weight-loss counterpart ... said many of his patients report life-changing weight loss while on GLP-1 medications. "I have some veterans who have lost 70 to ...